Taevas
AustraliaPharmaceuticals
Product Registration
Product Registration for Pharmaceuticals in Australia
Taevas Global helps pharmaceutical manufacturers navigate the Therapeutic Goods Administration registration pathway and secure ARTG inclusion to enter the Australian market with confidence and speed.
Market
Australia
Industry
Pharmaceuticals
Service
Product Registration
Regulator
Therapeutic Goods Administration (TGA)
Timeline
6-12 months (standard evaluation pathway)
What We Deliver
Six Pillars of Australia Pharmaceuticals Intelligence
Our six interconnected pillars give pharmaceutical manufacturers a complete view of regulatory requirements, market dynamics, and commercial pathways needed to register and succeed in Australia.
01
TGA Regulatory Pathway Analysis
We map the most appropriate registration pathway for your pharmaceutical product under the Therapeutic Goods Act 1989, whether that is a prescription medicine, over-the-counter product, or complementary medicine. Our team assesses ARTG inclusion requirements, registration versus listing distinctions, and any applicable international recognition pathways such as the AUSFTA or ACPM routes. This analysis prevents costly pathway misalignment before dossier preparation begins.
Prescription, OTC, and complementary medicine pathway mapping
ARTG registration versus listing determination
International recognition pathway eligibility assessment
How It Works
From Brief to Board-Ready Intelligence
Our four-phase engagement moves from initial scoping through deep regulatory research, dossier-ready deliverable production, and a live briefing that equips your team to act immediately.
Step 1 · Day 1-2
Scoping and Intake
We conduct a structured intake session to understand your product profile, existing global dossier status, target indication, and commercial timeline. Our team reviews any prior regulatory interactions and identifies the most efficient Australian registration pathway. A tailored project plan and timeline are issued within 48 hours of engagement.
Taevas Approach
The intake process captures active ingredient details, formulation type, therapeutic indication, proposed scheduling under the Poisons Standard, existing ICH CTD modules, and any prior TGA or comparable agency correspondence. This allows us to immediately identify pathway eligibility, likely evaluation category, and any pre-submission meeting requirements with TGA.
Market Snapshot
Australia Pharmaceuticals Market at a Glance
$0B
Annual Pharmaceuticals Market Size (AUD)
0%
Projected Annual Market Growth Rate
0+
Products on the ARTG (Prescription Medicines)
0+
New TGA Applications Lodged Annually
TGA as a Recognised Global Regulator
The TGA is a member of the International Council for Harmonisation and the Pharmaceutical Inspection Co-operation Scheme, meaning its standards are aligned with the FDA, EMA, and Health Canada. This alignment allows manufacturers with existing ICH-compliant dossiers to adapt rather than rebuild their submissions for Australia. TGA's participation in the ACTA mutual recognition framework with New Zealand further streamlines access to both markets simultaneously.
Stringent GMP and Overseas Manufacturer Oversight
All overseas manufacturers supplying medicines to Australia must hold a valid TGA GMP clearance, which is assessed through a desktop review of overseas regulatory authority inspection reports or a TGA overseas GMP inspection. Clearance is product-specific and must be renewed periodically, making proactive GMP compliance management essential for uninterrupted supply. Failure to maintain GMP clearance is one of the most common causes of supply disruption for imported pharmaceuticals in Australia.
PBS as the Primary Commercial Access Gateway
Approximately 85 percent of prescription medicines dispensed in Australia are subsidised through the Pharmaceutical Benefits Scheme, making PBS listing the primary commercial milestone after TGA registration. The Pharmaceutical Benefits Advisory Committee evaluates submissions on the basis of comparative clinical effectiveness and cost-effectiveness, requiring robust health economic modelling. Without PBS listing, most prescription products face severely limited commercial uptake in the Australian market.
Growing Biosimilars and Generics Opportunity
Australia has a well-established generic medicines market supported by TGA's abbreviated registration pathway for generics and a growing biosimilars framework aligned with EMA guidelines. The Australian government actively encourages biosimilar uptake through PBS pricing policies and prescriber incentives, creating significant commercial opportunity for manufacturers with approved biosimilar pipelines. The biologicals framework under the Therapeutic Goods Act provides a distinct regulatory pathway for biological medicines, including separate classification tiers based on manufacturing risk.
What's Included
Everything in Your Report
Every Product Registration engagement for Australia Pharmaceuticals delivers eight structured outputs designed to take your team from regulatory uncertainty to submission-ready confidence.
TGA Pathway Selection Report
A documented analysis of the optimal registration pathway for your product, including evaluation category, estimated TGA fees, and timeline benchmarks based on current TGA performance data.
CTD Gap Analysis Document
A module-by-module review of your existing dossier against TGA's Australian Regulatory Guidelines, identifying missing data, format non-conformances, and priority remediation actions.
ARTG Precedent Research Summary
A curated review of comparable approved products on the ARTG, including delegate decisions, approved indications, and labelling benchmarks to inform your submission strategy.
Poisons Standard Scheduling Assessment
A formal assessment of your product's scheduling classification under the current Poisons Standard and guidance on any scheduling proposal required before or concurrent with TGA registration.
Australian Sponsor and Distribution Map
A shortlist of qualified Australian sponsors and third-party logistics providers, with a structured evaluation framework covering capability, therapeutic area experience, and commercial terms.
GMP Clearance Readiness Assessment
An evaluation of your manufacturing sites' current GMP status relative to TGA clearance requirements, including identification of any inspection history gaps or documentation deficiencies.
Post-Market Compliance Roadmap
A 12-month post-approval compliance calendar covering pharmacovigilance reporting obligations, variation procedures, annual sponsor returns, and ARTG maintenance requirements.
PBS Reimbursement Readiness Brief
An executive-level assessment of your product's PBS listing prospects, PBAC evidence requirements, and recommended timeline for initiating the reimbursement submission process.
Who This Is For
Built for These Situations
First-Time Market Entrant
International Manufacturer Entering Australia for the First Time
Your product is approved in the US, EU, or Asia and you are evaluating Australia as your next commercial market. You have an ICH-compliant dossier but limited familiarity with TGA-specific requirements, Australian scheduling law, and the PBS reimbursement system. You need a trusted partner who can translate your existing global regulatory assets into an Australian submission without rebuilding from scratch.
Outcome
A clear pathway selection, a prioritised dossier gap list, and a submission-ready plan within four weeks of engagement.
Next Steps
After Product Registration, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your Australia Opportunity?
Whether you are preparing your first TGA submission or expanding an existing Australian portfolio, Taevas Global provides the regulatory expertise and market intelligence to get your pharmaceutical product registered and commercially launched in Australia.
TGA pathway selection and dossier gap analysis delivered within two weeks
End-to-end submission management from CTD preparation to ARTG inclusion
PBS reimbursement strategy aligned with your TGA registration timeline
Vetted Australian sponsor and distribution partner introductions